Table 2 APOE genotypes and allele frequencies by pathologically defined groups
From: Assessment of genetic risk for improved clinical-neuropathological correlations
N (%) | |||||||
|---|---|---|---|---|---|---|---|
APOE genotype frequency | ε4 allele frequency | ||||||
2/2 | 2/3 | 2/4 | 3/3 | 3/4 | 4/4 | ||
Control | 1 (1) | 25 (14) | 7 (4) | 119 (67) | 24 (14) | 1 (1) | 33 (9) |
FTD | 0 (0) | 7 (11) | 1 (2) | 37 (58) | 19 (30) | 0 (0) | 20 (16)† |
DLB | 0 (0) | 8 (14) | 4 (7) | 28 (50) | 16 (29) | 0 (0) | 20 (18)*† |
AD + DLB | 2 (0) | 11 (2) | 5 (1) | 136 (31) | 224 (51) | 64 (14) | 357 (40)* |
AD | 0 (0) | 52 (3) | 51 (3) | 594 (33) | 829 (46) | 273 (15) | 1426 (40)* |
AD + MTLS | 0 (0) | 8 (5) | 5 (3) | 58 (33) | 83 (47) | 21 (12) | 130 (37)* |